New pill hopes to tame severe gut disease in kids

NCT ID NCT07470879

Recruiting now Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a daily pill called etrasimod in 24 children aged 2 to 12 with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. The goal is to see if the drug can safely help children reach remission (few or no symptoms) over 52 weeks. Participants who finish may continue treatment for up to 5 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Etrasimod (a daily pill that helps control inflammation in the gut)
What this could lead to: If successful, this could provide a new treatment option for children with ulcerative colitis, helping them achieve and maintain remission.
What could go wrong: This is a small, early-phase study with only 24 children, so results may not apply to all patients. The drug may cause side effects or fail to show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colitis ulcer disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLITIS, ULCERATIVE

Contacts and locations

Locations

Azienda Ospedaliera Universitaria Meyer IRCCS
NOT_YET_RECRUITING

Florence, Tuscany, 50139, Italy
CHU de Québec - Université Laval
RECRUITING

Québec, Quebec, G1V4G2, Canada
Centrum Zdrowia MDM
RECRUITING

Warsaw, Masovian Voivodeship, 00-189, Poland
Children's Hospital Research Institute of Manitoba
NOT_YET_RECRUITING

Winnipeg, Manitoba, R3E 3P4, Canada
Evelina London Children's Hospital
RECRUITING

London, SE1 7EH, United Kingdom
Gyncentrum sp. z o.o. NZOZ Holsamed - oddział Libero
RECRUITING

Katowice, 40-600, Poland
HELIOS Klinikum Wuppertal
RECRUITING

Wuppertal, 42283, Germany
Hadassah Medical Center
RECRUITING

Jerusalem, Jerusalem, 9112001, Israel
Health Sciences Centre Winnipeg
NOT_YET_RECRUITING

Winnipeg, Manitoba, R3A 1S1, Canada
Hospices Civils de Lyon - Hôpital Femme Mère Enfant
RECRUITING

Bron, Auvergne-Rhône-Alpes, 69500, France
Hôpital Universitaire Necker Enfants Malades
NOT_YET_RECRUITING

Paris, 75015, France
Instytut "Pomnik - Centrum Zdrowia Dziecka"
RECRUITING

Warsaw, 04-730, Poland
Japanese Red Cross Kumamoto Hospital
RECRUITING

Kumamoto, 861-8520, Japan
Juntendo University Hospital
RECRUITING

Tokyo, 113-8431, Japan
King's College Hospital
NOT_YET_RECRUITING

London, London, CITY of, SE5 9RL, United Kingdom
Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor Kierkuś
RECRUITING

Warsaw, Masovian Voivodeship, 04-501, Poland
Rambam Health Care Campus
NOT_YET_RECRUITING

Haifa, Northern District, 3109601, Israel
Saitama Prefectural Children's Medical Center
RECRUITING

Saitama-shi, Saitama, 330-8777, Japan
Shaare Zedek Medical Center
RECRUITING

Jerusalem, Jerusalem, 9013102, Israel
Sheba Medical Center
NOT_YET_RECRUITING

Ramat Gan, Central District, 5262100, Israel
Sheffield Children's Hospital
RECRUITING

Sheffield, S10 2TH, United Kingdom
Universitaetsklinikum Tuebingen
RECRUITING

Tübingen, 72076, Germany
Universitätsklinikum Leipzig
NOT_YET_RECRUITING

Leipzig, Saxony, 04103, Germany
Universitätsklinikum Münster - Albert Schweitzer Campus
NOT_YET_RECRUITING

Münster, North Rhine-Westphalia, 48149, Germany
Yitzhak Shamir Medical Center
NOT_YET_RECRUITING

Ẕerifin, Central District, 70300, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.